Shots:

• The sNDA is based on P-III EMPEROR-Preserved trial evaluates the safety and efficacy of Jardiance (10mg, qd) vs PBO in 5,988 patients with chronic HFpEF with/out diabetes
• The results showed a 21% reduction in relative risk for the composite 1EPs of CV death or hospitalization in adults with HF with LVEF The results were presented at ESC 2021 and published in NEJM
• The therapy has previously received FTD from the US FDA to reduce the risk of CV death and hospitalization for HF & is currently indicated for adults with HFrEF. If Jardiance is approved, it will be the first clinically proven treatment for patients with HF regardless of ejection fraction

Ref: PR Newswire | Image: Boehringer Ingelheim